Compare Salesforce Inc (CRM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs Neurocrine Biosciences Inc — how do they compare? Salesforce Inc trades at $228.96 (market cap $187.48B), while Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B). The key difference: Salesforce Inc is far larger — about 13.1× Neurocrine Biosciences Inc's market cap, and Salesforce Inc pays a 0.77% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and Neurocrine Biosciences Inc for 23 Days on average.
| CRM | NBIX | |
|---|---|---|
Market Cap | $187.48B | $14.36B |
Volume | 6,155,822 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $266.23 | $185.50 |
52-Week Low | $150.12 | $123.10 |
Typical Hold Time | 89 Days | 23 Days |
Enterprise Value | $217.82B | $14.37B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $229.13, up 2.04% today, showing strong fundamental performance with consistent earnings beats and robust revenue growth. The company maintains exceptional profitability with 77.28% gross margins and 21.99% net income margins. Technical indicators show a bearish trend with the stock trading near resistance at $230, while analyst consensus remains strongly bullish with a $271.91 price target representing 19% upside potential.
CRM presents a compelling investment opportunity with strong AI monetization growth and improving profitability, though facing near-term technical headwinds and software sector volatility. The stock trades at reasonable valuations (P/E 20.86) with solid cash flow generation, but investors should monitor competitive pressures and macroeconomic impacts on enterprise software spending.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
